The Pathways Related to Glutamine Metabolism, Glutamine Inhibitors and their Implication for Improving the Efficiency of Chemotherapy in Triple-Negative Breast Cancer

Publication date: Available online 18 January 2021Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Soheila Delgir, Milad Bastami, Khandan Ilkhani, Asma Safi, Farhad Seif, Mohammad Reza Alivand
Source: Mutation Research Reviews in Mutation Research - Category: Genetics & Stem Cells Source Type: research

Related Links:

Conclusions: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractBackgroundDespite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF.MethodsWomen with stage I –III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCA M...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThe study showed that analysis of MP grades combined with the 70-gene signature with residual NAC-resistant breast samples has a significant correlation with DFS.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: TAS selectively reduced the tumor load in the axilla and remained much less radical than ALND.PMID:34555676 | DOI:10.1016/j.breast.2021.09.004
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Sequential administration of eribulin after the A/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.PMID:34554370 | DOI:10.1007/s10549-021-06396-0
Source: Cell Research - Category: Cytology Authors: Source Type: research
J Clin Oncol. 2021 Sep 23:JCO2101757. doi: 10.1200/JCO.21.01757. Online ahead of print.NO ABSTRACTPMID:34554850 | DOI:10.1200/JCO.21.01757
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
J Clin Oncol. 2021 Sep 23:JCO2101537. doi: 10.1200/JCO.21.01537. Online ahead of print.NO ABSTRACTPMID:34554822 | DOI:10.1200/JCO.21.01537
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clin Exp Med. 2021 Sep 23. doi: 10.1007/s10238-021-00761-5. Online ahead of print.ABSTRACTPseudopodium-enriched atypical kinase 1 (PEAK1) has been reported to be upregulated in human malignancies and is correlated with a poor prognosis. Enhanced PEAK1 expression facilitates tumor cell survival, invasion, metastasis and chemoresistance. However, the role of PEAK1 in breast cancer is unclear. We investigated PEAK1 expression in breast cancer and analyzed the relationship with clinicopathological status and chemotherapy resistance. We also investigated the role of PEAK1 in breast cancer cells in vitro and in vivo. Immunohisto...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Expert Opin Drug Saf. 2021 Sep 22. doi: 10.1080/14740338.2021.1983541. Online ahead of print.ABSTRACTINTRODUCTION: Thanks to the emergence of new therapeutics, prognosis and outcome of breast cancer patients (any subtype) have improved significantly. This raises the issue of the interactions and side effects related to the use of multiple drugs. Thus, to decide on a treatment the optimal benefit risk-ratio should be carefully watched as toxicities such as cardiac ones effect on long-term survival. Indeed, nowadays in France, cardiovascular diseases rank first as causes of death in women.AREAS COVERED: This non-exhaustive r...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics